Clinical Trial Update: Study to Assess Safety and PET Imaging Characteristics of a Novel Senescence-specific Radiotracer [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a novel radiotracer [18F]FPyGal targeting senescence, in Phase 1/2 for cancer, with unknown current status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• [18F]FPyGal (2-[Fluorine-18]Fluoro-3-pyridinyl-β-D-galactopyranoside) (null)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: Cancer | Phase 1, Phase 2 | Status: UNKNOWN